Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r

WEDNESDAY, April 25, 2018 -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news